Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Allied Physicians Inc

Neither a doctor nor a teaching hospital

Research payments

$1,727,681

318 payments

Through program year 2025, Allied Physicians Inc is reported as receiving $1,727,681 in research payments, across 318 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $335,116 7
2024 Research $401,170 17
2023 Research $197,265 59
2022 Research $329,865 94
2021 Research $40,882 25
2020 Research $238,785 37
2019 Research $184,599 79

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $670,886 4 payments
  2. Genzyme Corporation $340,606 37 payments
  3. AbbVie, Inc. $136,473 38 payments
  4. Ucb SA $114,454 13 payments
  5. Ipsen Pharma SAS $92,374 57 payments
  6. Genentech, Inc. $84,276 18 payments
  7. H. Lundbeck A S $61,972 11 payments
  8. Eisai Inc. $52,277 11 payments
  9. Allergan Inc. $42,504 11 payments
  10. Alexion Pharmaceuticals, Inc. $40,051 32 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib $670,886 4 payments
  2. A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis $229,250 30 payments
  3. A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity $89,341 55 payments
  4. A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of padsevonil as adjunctive treatment of focal-onset seizures in adult subjects with drug-resis $71,083 5 payments
  5. A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) $70,033 5 payments
  6. Postgraduate Roll Over Study $62,834 16 payments
  7. Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine $55,583 13 payments
  8. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $52,277 11 payments
  9. A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy $42,458 9 payments
  10. A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS03409) $41,323 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record